Chimagen Biosciences

News

GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.

News

The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.

Sales & Marketing

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.